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ABSTRACT
According to Food and Drug Administration (FDA), therapeutically equivalent antibiotics is
expected to have equivalent clinical efficacy and safety when used under the conditions of their
labeling. However, any defect in the quality of an antibiotic may negatively affect its efficacy and
safety and accordingly are considered a substandard drug. Cefuroxime is a semi-synthetic, broadspectrum cephalosporin antibiotic intended for oral administration. Any quality defect in this product may cause inefficacy and future bacterial resistance. The aim of this study was to evaluate the
quality and cost price of all commercial Cefuroxime axetil tablet products available on the Palestinian market (One brand and two generic products). A survey on the price of all commercial tablet
products was conducted. To assess quality, all products were examined visually for their general
appearance. They were tested for weight uniformity, friability, disintegration, and dissolution profile, and assayed for Cefuroxime content. The original brand was more expensive than the two locally produced generic products. Based on our testing procedure, all Cefuroxime tablet products
were equivalent to the brand product. Although, the two generic products released more than 85%
of their Cefuroxime content within 15 minutes, while the brand released only 74.5%. These results
demonstrate that generic Cefuroxime tablets produced by local manufacturers are often comparable
in vitro to the brand product and have lower price. Accordingly, we encourage our physician to
prescribe the local product since they may be interchangeable and have same safety and efficacy
profile.
Keywords: Cefuroxime Axetil, Tablet, Analysis, Interchangeability, Price.
Aerobic Gram-negative Microorganisms and
Spirochetes (2).
INTRODUCTION
Cefuroxime axetil is a second generation
cephalosporin with a broad-spectrum antibacterial activity intended for oral (PO) administration. It is (RS)-1-hydroxyethyl(6R,7R)7-[2-(2-glyoxylamido]-3-(hydroxymethyl)-8oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2carboxylate, 7-(Z)-(O-methyloxime), 1acetate 3-carbamate (Fig. 1). Cefuroxime
acts by interfering with the peptidoglycan
synthesis of the bacterial cell wall resulting
in inhibition of the final transpeptidation
needed for the cross-links (1). It is effective
against wide range of microbes including
Aerobic Gram-positive Microorganisms,
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Figure (1): Chemical structure of cefuroxime
axetil.
Cefuroxime axetil has a good pharmacokinetic behavior such that it is well absorbed
from gastrointestinal (GI) tract and is rapidly
hydrolyzed in the intestinal mucosa and
blood to cefuroxime. Peak plasma concentration was reported to range between 2 to 3
hours after PO administration. With regards
to its elimination manner, cefuroxime is excreted unchanged (about 95%) by glomerular
filtration and renal tubular secretion with a
terminal elimination half-life of 1.5 hour (3).
In addition, cefuroxime is widely distributed
in the body fluids. It has the capacity to pass
through the placenta and is excreted with
milk in lactating mother. Approximately,
33% of cefuroxime is bound to albumin (4).
However, the pharmacokinetic data could be
influenced by food administration. The extent
of cefuroxime systemic absorption is enhanced when taken with food as its absolute
bioavailability rises to reach approximately
50%.
Nevertheless, Finn and co-workers
demonstrated that despite this alteration in
absorption, the clinical effects and antibacterial activity were not affected by food intake
at the time of tablet administration (5). Likely
to other antibiotics, cefuroxime may interfere
with oral contraceptive efficacy because of
decreases estrogen re-absorption (6). Although the desired therapeutic effect that Cefuroxime gives as antibiotic, it like other
medicines causes some side effects such as
diarrhea , feeling or being sick, stomachache,
headache, dizziness and penicillin allergic
patients have a 5% to 10% incidence to have
a
cross-hypersensitivity
reaction
to
cephalosporins (7). Cefuroxime axetil is
marketed in Palestine under three trade
names (Zinnat®, Zinex® and Zinaxim®).
It is formulated either as an oral solid
dosage form such as film-coated tablets containing 250 or 500 mg of Cefuroxime or as
oral suspension containing 125, 250 mg of
the same API. During the development of
generic dosage forms, pharmaceutical scientists play an important role in the selection of
excipients and manufacturing process. In
fact, these two factors have huge impact on
the final quality and therapeutic outcomes of

the obtained products. Wrong selection of
these factors will result in substandard products. One of the most important problems
that facing antibiotics is the growing resistance of microorganism due to the irrational use of these antibiotics or due to substandard quality of the produced dosage
forms containing antibiotics. Therefore, regularly, investigations of the quality of medicines in the pharmaceutical market are crucial. Such aspects may include the extent of
availability of counterfeit pharmaceuticals in
the local market and to what extent generics
were comparable to the originator (branded)
medicine. The quality of pharmaceutical
products might be assessed by visual examination, quantitative and qualitative identification pharmacopoeial analysis. Ideally, analysis of pharmaceutical products starts during
manufacturing and continues after registration and marketing. However, only few countries have regulatory authorities that analyze
pharmaceutical products before and after registration (8).
The quality of oral tablets and other drug
dosage forms must be built in during different stages of production, testing, storage and
distribution (9). However, the quality of end
product is not guaranteed. The essential qualities of good compressed tablet are characterized by a number of specifications. These
include the appearance, size, shape, thickness, weight, homogeneity, stability, hardness, dissolution time, and disintegration
time. All such qualities are designed to ensure a safe, therapeutically, effective oral
solid dosage form. Official QC tests for tablets or Compendial tests (i.e., pharmacopeial)
include; uniformity of content of the API
(i.e., Uniformity of weight & Content uniformity), disintegration test, dissolution test
and friability test.
However, there are other tests that are
frequently applied to tablets for which there
are non-pharmacopoeial requirements but
will form a part of manufacture's owner
product
specifications.
These
noncompendial tests include color, shape, tablet
thickness, tablet hardness and tablet volume.
Accordingly, this study was conducted in
order to evaluate the quality of commercially
Cefuroxime axetil tablet products available
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on the Palestinian market and to assess if
there any justification for their market price.
MATERIALS AND METHODS
Chemicals and reagents
All chemicals and reagents including Cefuroxime axetil powder, hydrochloric acid,
potassium chloride and monobasic ammonium phosphate were kindly supplied by Jerusalem Pharmaceuticals Co. Ltd. (Ramallah,
Palestine). HPLC-grade and analytical grade
methanol was obtained from Fisher Scientific
(Loughborough, UK). The purified water

used for preparing solutions and mobile
phase was obtained from water system
(Stilmas, Italy). The examined tablets were
purchased from the local market in just the
same way that the patient might have bought
them from a community pharmacy. All products have a labeled Cefuroxime content of
500 mg. All tested products were within their
shelf lives and were manufactured within the
same period (i.e., March 2016). A list of the
tested products is shown in Table 1.

Table (1): A list of the tested commercial tablets of cefuroxime axetil available on the Palestinian
market.
Product
A
B
C
(reference)

Physical
ance

appear-

Oblong biconvex
caplet shape
Oblong biconvex
caplet shape
Oblong biconvex
caplet shape

Classification
Local
Local
Imported (brand)

Methods and instrumentations
All methods used to determine the quality of the tablet products were conducted according to the United State Pharmacopeia
(10). All tests were performed within product
expiry dates. Before starting the study, the
Palestinian Medicines Index (PMI) and the
Israeli Medical Index (MEDIC, 2013 edition)
were consulted to determine the brands
which are currently available on the Palestinian market. Uniformity of dosage unites was
assessed according to the following procedure: a set of 10 tablets was chosen randomly
and weighed individually using high sensitivity analytical balance (Erweka, Germany).
The weight variation was assessed by weighing 20 tablets individually for all of the tested
products. The average weight and the standard deviation were determined and the percentage deviation from the mean of each tablet was calculated. The USP acceptance criteria for weight variation test is “Not more than
two of the individual weights deviates from
the average weight by more than 5% and
none deviates by more than 10%. Hardness
test was performed on 10 tablets by simulta-

Manufacturing
date (Expiration
period)
March 2016 (3
years)
March 2016 (3
years)
March 2016 (3
years)

Price
USD /10tablets
10.5
10.5
14

neously measuring the thickness (mm),
length (mm), width (mm) and crunching
strength or hardness (N) using a hardness
tester (Erweka TB24, Germany). For the purpose of determination of the volume of each
product, the displacement method was used.
A 25-mL calibrated graduated cylinder in 0.1
mL divisions was employed using a silicon
oil as a soaking solvent. Five tablets of each
of the tested product were immersed and the
observed change in oil level was obtained,
afterwards, the average volume was calculated.
Tablet disintegration time was also assessed, the test accomplished by introducing
6 tablets into the tubes of the rack assembly
of a disintegration tester (Erweka ZT 320,
Germany). The assembly was suspended in
1000 mL simulated gastric fluid (SGF) pH
1.2 maintained at 37◦C and the apparatus was
operated for a specified time until no fragments of un-dissolved tablets observed on the
sieve of the apparatus. The device was set for
raising and lowering in the basket in the immersion fluid at constant frequency rate between 29 and 32 cycles per minute. Drug release studies were performed according to the
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USP apparatus II paddle method using a dissolution apparatus (Erewka, Heusenstamm,
Germany). The paddles were rotated at 55
rpm and the temperature was kept at 37 ± 0.5
◦
C. Dissolution vessels were filled with 900
mL of SGF. All SGF was prepared using
0.07 N hydrochloric acid. Samples were
withdrawn at 15 and 45 minutes, filtered,
diluted as appropriate and measured at 278
nm using Ultra violet (UV) Spectrophotometer (Shimadzu UV 1700).
All chromatographic experiments were
performed using a High performance liquid
chromatography (HPLC) system (Dionex UltiMate 3000 LC System, USA) consisting
of a pump, auto-sampler injector and a UV
detector. All LC parts were controlled by
Chromeleon® version 6.80 (Dionex). Separations were done on a reversed phase column
using the LC method described earlier in accordance to the USP procedures (10); the
method provided a quantitative determination
of the content of Cefuroxime axetil as API in
the tested medicines. However, a brief description for standard preparation was shown
here; “Transfer about 30 mg of Cefuroxime
axetil to a 25 mL volumetric flask, dissolve
in methanol, dilute with Methanol to volume,
and mix. Promptly transfer 10.0 mL of this
solution to a 50 mL volumetric flask and then
dilute with 0.2 M MAP to volume, and mix”.
The area under the peak (AUP) from the
chromatogram was obtained for this standard
solution and then was used to determine the
content of Cefuroxime in the tablets.
Related substances examined in accordance to British Pharmacopeia (BP) (11) in
which the LC method used as described under assay. The method was performed by
preparing test solution to dissolve tablet substance equivalent to 10 mg of cefuroxime
axetil in to the mobile phase and dilute to 50
ml with the mobile phase. Reference solution
(1) prepared by diluting 1 ml of test solution
to 100 ml with the mobile phase, for reference solution (2) heat 5 ml of test solution at
60° for 1 h to generate the ∆3-isomers and
for reference solution (3) expose 5 ml of test
solution to ultraviolet light at 254 nm for 24
h to generate E-isomers. Reference solution
(4) prepared by dissolving 10 mg of cefuroxime axetil in the mobile phase and dilute to

50 ml with the mobile phase. Inject 20 µl
each of reference solutions (1-4) and chromatograms recorded at 278 nm with a flow rate
of 1.5 ml/min. Percentage content of the related substances calculated from the areas of
the peaks in the chromatogram by the normalization procedure.
RESULTS
Only three different commercial products of Ceferuxime tablets (500 mg/tablet)
are available on the Palestinian pharmaceutical market (two locals and one brand). They
were classified into brand and locally produced products and they were analysed for
price to public. The results showed that both
local products had same cost price and was
approximately 33% less expensive than the
original brand (Table 1). This may raise a
question about the quality of these products
and if the can be interchangeable or not.
In fact, according to FDA, products
evaluated as therapeutically equivalent can
be expected to have equivalent clinical efficacy and safety when used under the conditions of their labeling. However, these products may differ in the following characteristics: shape, scoring configuration, release
mechanisms, packaging, excipients (including colors, flavors, and preservatives), expiration date/time, and, sometimes may have
different labels. Therefore, if these products
are substituted, there is a potential for patient
confusion due to differences in color or shape
of tablets. Moreover, inability to provide a
given dose using a partial tablet if the proper
scoring configuration is not available, or decreased patient acceptance of certain products because of flavor or taste. There may
also be better stability of one product over
another under adverse storage conditions, or
allergic reactions in rare cases due to a coloring or a preservative ingredient, as well as
differences in cost to the patient (12).
Accordingly, visual quality was used to
examine and to evaluate the organoleptic
properties due to the impact of these properties on patient compliance. The appearance
of tablets of the selected brands was elegant
and their color, size, texture were consistent
with no sign of defects in all tested tablets. In
fact, no one of the tested commercial prod-
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ucts had one of the above advantages on the
other.
Regarding
the
instrumental
and
compendial inspection, our data as expected
showed that weight variation was found to be
within the pharmacopeial limits. The deviation from the average weight results revealed

that products A, B and C had the following
range limits (97.68 - 102.50%), (96.75 102.97%) and (99.21 -104.25%) respectively
in which no tablet was out of the USP allowed limit (i.e. NMT 5%). Table 2 provides
a summary of the some quality tests.

Table (2): Weight variations, product’s dimensions and hardness tests.

Product

Average
weight ± (mg)
RSD%

Thickness
(mm)

Length
(mm)

Width
(mm)

Estimated
Volume
(cc)

Tablet
hardness
mean ± SD

A

937.4 ± 2.56

6.77 ± 0.08

19.11 ± 0.02

9.14 ± 0.06

0.95

16.10 ± 3.50

B

1247.3 ± 0.82

8.14 ± 0.02

20.31 ± 0.22

9.78 ± 0.08

0.95

19.18 ± 0.85

C

912.2 ± 1.32

5.78 ± 1.3

19.63 ± 0.01

8.31 ± 0.03

0.87

23.51 ± 1.20

Tablet hardness, tablet thickness and
length results of the different tested products
were also assessed and our findings were reported in Table 2. The size of the tablet was
estimated to assess swallowing problems
which represents a persistent challenge especially in elderly individuals and patients who
have dysfagia or have experienced an oesophageal ulceration after tablet or capsule
swallowing. The time required for complete
disintegration of all tablets containing Cefuroxime (500 mg) was tested according to
the pharmacopeial guidelines. The results
demonstrated that time for disintegration of
both formulations A and C was about 1 minute. However, the time needed to disintegrate product B was about 2 minutes. The
percentage of dissolved CA in each product

was determined at 2 time points particularly,
15 and 45 minutes according to the USP
monograph. The test was performed using
dissolution apparatus II as described earlier.
The result showed that all products passed
this test in the first stage of dissolution testing. The USP acceptance criteria of tablets
labeled to contain the equivalent of 500 mg
cefuroxime state that “Tolerances: not less
than 50% (Q) of the labeled amount is dissolved in 15 minutes and not less than 70%
(Q) is dissolved in 45 minutes”. Where, Q, is
the amount of dissolved active ingredient
specified in the individual monograph, expressed as a percentage of the labeled contents. The percentages of drug release in all
examined units were more than 55 and 75%
at 15 and 45 minutes respectively (Table 3).

Table (3): Dissolution and disintegration time results of all Cefuroxime axetil tablets on the Palestine market.

Product
A
B
C

Disintegration time
USP Limit (NMT 15 min)
1
2
1

The amount of Cefuroxime in each tablet
of the examined pharmaceuticals was determined using the HPLC method. The estimated percentages per labels, from the assay,
together with their relevant statistical analysis, are shown in Table 4. The USP 2014

Dissolution
Average % of dissolved CA
15 min.
45 min.
74.5 ± 5.5
91.8 ± 4.6
88.0 ± 3.1
100. 1 ± 1.5
93.15 ± 1.6
96.18 ± 2.2

specifies a range of 90 -110% of the stated
amount of Cefuroxime tablets. Accordingly
all of the tested tablets were complies with
the USP specifications. In addition, the obtained results pertaining related substances
were summarized in Table 4.
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Our findings suggest that all of the tested
products met the pharmacopoeial specifications regarding related substances. Figure 2

shows a representative chromatogram of related substances test under the chromatographic conditions explained earlier.

Table (4): Assay and related substances results of the tested products with their statistical parameters.
Product
Pharmacopeial
limit
A
B
C

Average Assay
(%) ± SD (n =
10)

Related substances (%)
E 1 enantio∆3-isomer
mer

90-110%

NMT 2.0%

Sum NMT 1.5%

98.51±0.52
98.57±0.44
97.38±0.91

0.9
0.9
1.3

0.2
0.1
0.0

E 2 enantiomer

Other impurities
NMT 1.0%

0.1
0.1
0.0

0.49
0.16
0.1

Figure (2): obtained chromatogram for related substances test.
DISCUSSION
Palestine relies under the Israel occupation and this impact negatively on many aspect of Palestinian occupation, especially the
economic side. In fact, Palestine is considered a low income country. However, many
patients try to not save many when the issue
is related to medication. According to local
community pharmacists and physicians, patients usually prefer imported drugs since
they believe that these products have superior
therapeutic effect and safety than the locally
produced products. Many of these patients
can pay a higher price for brand products
despite the poor economic circumstances of
many of them. Many of care providers also
have this belief and sometimes encourage
patients to buy the brand products. The objective of this study was to survey Cefuroxime tablet products available on the Palestinian pharmaceutical market according to their
price and to assess their quality according to

pharmacopeial
and
non-pharmacopeial
standards in order to identify if these products could be interchangeable.
Quality control tests and specifications
for some of the experimental part of the current study are given in pharmacopoeia. The
most important for these are; weight uniformity, the drug release in terms of tablet
disintegration and drug dissolution, resistance of tablets to fracture in terms of friability and hardness testing of the product.
Previous studies have shown alarming serious levels of substandard medicines in some
Arab and developing countries (8, 13-15).
Indeed, the major aim of the research project
was to investigate if the local medicines are
comparable with the imported products and
hence, their interchangeability may be granted. The Palestinian Ministry of Health
(MOH) and the Department of Drug Control
and Registration (DDCR) are the regulatory
authorities that grant marketing authorization
for branded and generic drug products. Ac-
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cording to the current regulation (16), a
product has to satisfy the compendial requirements for safety, purity and quality according to either the USP or the British
Pharmacopeia (BP). Additionally, a bioequivalence study is required to show that the
generic is bioequivalent to the brand name
drug according to the USA Food and Drug
Administration (FDA) and the European
Medicines Agency (EMEA) (17, 18). The
Palestinian regulatory authorities recognize
and accept properly conducted studies performed in vitro to support in vivo data (19).
The result showed low price (one third less)
of Cefuroxime local product comparable the
original brand. In fact the cost of original
brand exceeds the local products about 4
USD for each box of course therapy. This
large price represents a negative impact on
the economical situation of both patients and
Palestinian MOH. A visual QC examination
was carried on all Cefuroxime tablet selected
in this study for the purpose of evaluating
their organoliptic properties (i.e., shape, size,
color, texture and presence of black spots). In
fact, these parameters play a very important
role in patient’s acceptance or compliance
toward any dosage form. With regard to tablet strength, all the tested products passed the
friability test demonstrating that these products do not lose Cefuroxime during the transportation or handling process. However, high
tablet strength should not compromise disintegration in the stomach.
Besides, the tablet size may be associated with swallowing problems. In fact, the
drug induced oesophageal ulceration is a serious problem and is due to a delay in the
passage of the tablet or capsule because of
their sticking in the oesophagus. Indeed, several recommendations were proposed to
avoid this problem. Among these recommendations; the use of a low size tablets or capsules, taking appropriate body posture and
drink at least 100 mL of water or other appropriate carrier.
Concerning dissolution, this test is used
as a tool in order to ensure products quality
and batch to batch variability. It is also used
as an alternative tool for the assessment of in
vivo bioequivalence. In vivo bioequivlence
studies are conducted in healthy volunteers.
These studies are costly, time consuming and

involve subjecting healthy volunteers to risks
of side effects. However, today regulatory
agencies like the FDA and the EMEA allow
the replacement (waiver) of in vivo
bioequivelence studies by in vitro dissolution
testing especially for class 2 drugs (highly
soluble, highly permeable. Accordingly the
in vitro dissolution test is used to predict the
in vivo absorption of the drug product, by
means of in vivo/in vitro correlations
(IVIVC). The dissolution of the drug from
oral solid dosage forms is essential for drug
bioavailability, especially for slightly water
soluble drugs such Cefuroxime. For this reason, dissolution studies can give an idea of
the amount of drug available for absorption
after oral administration (19, 20). Drugs with
poor dissolution profiles will not be sufficiently available in the body system to produce the desired therapeutic response (21).
The dissolution profiles of all tested brands
were performed in Simulated gastric Fluid
(SGF) and they were found to be comparable.
More precisely the average release of cefuroxime in SGF from the local was greater
than 85% after 15 minutes while the brand
released about 74.5 % of its content after
same time and both local showed almost better drug release after 45 minutes than the
original bran which may encourage us to
conclude that the quality of these two local
products are of high standard.
CONCLUSIONS
The obtained results indicated that all of
the examined products were in accordance
with the pharmacopeial specifications. The
local products showed little significant differences compared to the original brand.
However, the price of the brand is higher
than the locally produced generics. Our findings signify that generic Cefuroxime tablets
produced by local manufacturers are often
comparable in vitro to the innovator product
(even have better drug release) and have
lower costs. According to the above mentioned findings, the local pharmaceutical
products containing cefuroxime axetil
showed comparable in vitro testing with the
originator. Hence, we should take in our consideration that the national pharmaceutical
industry need care-providers and inhabitants
to be confident in their products, since they

 ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــPalestinian Medical and Pharmaceutical Journal (PMPJ). 2016; 1(1): 7-14

14 “ ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــInvestigation of the Interchangeability between ......”

showed high quality standard with about 33%
save on the cost of each product.
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